• colloid;
  • small animal;
  • hypoalbuminemia;
  • hypotension


Objective: To report on the use of 25% human serum albumin (25% HSA) (Plasbumin®), associated outcome, and efficacy in raising serum albumin and systemic blood pressure (BP) in critically ill dogs and cats.

Design: Retrospective clinical study.

Animals: Client-owned cats and dogs.

Interventions: Administration of 25% HSA.

Measurements and main results: The medical records of 66 animals (64 dogs, 2 cats) at the Ontario Veterinary College, which received 25% HSA (Plasbumin®) from June 1997 to December 2001 were reviewed for age, body weight, clinical problems, albumin and globulin (g/L) levels pre- and within 18-hour post-transfusion and upon discharge from hospital, total solids (TS), systolic and diastolic BP pre- and post-transfusion total volume administered, adverse reactions, blood products and synthetic colloids used, and outcome. Twenty-five percent HSA was prescribed for a range of clinical problems, which were grouped into 6 categories for analysis. The age range was 4 months–12 years and body weight range 1.4–65 kg. The maximum volume administered to any dog was 25 mL/kg, mean volume administered was 5 mL/kg, maximum volume given as a slow push or bolus was 4 mL/kg with a mean of 2 mL/kg volume. The range for a constant rate infusion (CRI) was 0.1–1.7 mL/kg/hr over 4–72 hours. Forty-seven (71%) animals survived to discharge; 11(16%) were euthanized, and 8 (12%) died. Serum albumin and TS increased significantly (P<0.0001) above pre-transfusion levels as did systolic BP (P<0.01).

Conclusions: Twenty-five percent HSA can be safely administered to critically ill animals, and an increase in albumin levels and systemic BP can be expected.